An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study

Phase 3 Terminated 139 enrolled Axsome Therapeutics, Inc.

NaSingle-groupOpen-labelTreatment

Summary

The primary objective of this open-label extension trial was to evaluate the long-term safety of AXS-05 for the treatment of Alzheimer's disease agitation in subjects that participated in ADVANCE-2 or ACCORD-2.

Timeline

Start: 2024-11-21
Primary completion: 2025-02-17
Completion: 2025-04-25

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AXS-05	Unknown	—	Oral

An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study

Summary

Timeline

Drugs

Indications